Search
Menu
Rocky Mountain Instruments - Laser Optics LB

Spectranetics Meets Enrollment Target for LACI Phase 2 Study

Facebook X LinkedIn Email
COLORADO SPRINGS, Colo., April 15 -- The Spectranetics Corp. has reached the enrollment target of 137 registry patients in its LACI (laser angioplasty for critical limb ischemia) Phase 2 study, which tests use of the excimer laser to improve circulation to the lower leg. The company said it will continue enrolling patients in LACI Phase 2 in order to include its Extreme II peripheral excimer laser catheters, which were recently FDA-approved for the LACI study. Spectranetics said it plans to conclude enrollment in LACI Phase 2 no later than April 30, when LACI will enter a six-month follow-up...Read full article

Related content from Photonics Media

    Published: April 2002
    News & Features

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.